---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-017637"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-05-18T20:58:36+00:00"
generated_at: "2026-05-18T20:59:40.219237+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports Q1 2026 net loss of $8.0M; cash runway only into Sept 2026

## Summary
- Net loss $8.0M vs $4.9M YoY; no grant revenue vs $1.9M prior year.
- Cash, cash equivalents and marketable securities $12.9M as of March 31, 2026, down from $20.9M at Dec 31, 2025.
- Cash runway expected to fund operations into September 2026.
- Plans to initiate Phase 3 DLB trial in H2 2026, subject to financing.
- Presented new MRI and biomarker data at AAN 2026 and AD/PD 2026 supporting neflamapimod.

## SEC filing metadata
- accession: 0001437749-26-017637
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-05-18T20:58:36+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926017637/0001437749-26-017637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926017637/crvo20260518_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-017637
- JSON: https://secwatch.observer/filing/0001437749-26-017637.json
- Plain text: https://secwatch.observer/filing/0001437749-26-017637.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.